Literature DB >> 27215425

Prostate cancer: Prudent practice optimizes screening outcomes.

Anssi Auvinen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27215425     DOI： 10.1038/nrurol.2016.90

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.

Authors:  Joshua A Roth; Roman Gulati; John L Gore; Matthew R Cooperberg; Ruth Etzioni
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

2.  Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

Authors:  Reka Pataky; Roman Gulati; Ruth Etzioni; Peter Black; Kim N Chi; Andrew J Coldman; Tom Pickles; Scott Tyldesley; Stuart Peacock
Journal:  Int J Cancer       Date:  2014-02-04       Impact factor: 7.396

3.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506

4.  The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Authors:  Roman Gulati; Alex Tsodikov; Elisabeth M Wever; Angela B Mariotto; Eveline A M Heijnsdijk; Jeffrey Katcher; Harry J de Koning; Ruth Etzioni
Journal:  Cancer Causes Control       Date:  2012-04-10       Impact factor: 2.506

5.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

6.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

7.  A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.

Authors:  Anton Palma; David W Lounsbury; Nicolas F Schlecht; Ilir Agalliu
Journal:  Am J Epidemiol       Date:  2015-12-24       Impact factor: 4.897
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.